Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) | PAR 21 210

Opportunity Information: Apply for PAR 21 210

This funding opportunity (PAR-21-210) is an NIH National Institute of Mental Health (NIMH) R01 grant solicitation focused on effectiveness trials for post-acute interventions and services aimed at improving longer-term outcomes for mental health conditions across the lifespan, including youth, adults, and older adults. It is a reissue of PAR-18-430 and is specifically positioned to support clinical trials in real-world or practice-relevant settings that can answer the practical question of whether a given post-acute therapeutic or service-delivery approach works when implemented under typical conditions. The emphasis is on the phase after an acute episode or an initial course of treatment, when many patients still experience residual symptoms, functional impairment, elevated relapse risk, or difficulty staying engaged with care.

The core purpose of the program is to fund statistically well-powered, definitive effectiveness trials of interventions that fit the post-acute stage of illness. In this context, "post-acute" generally means the period when a person has completed an initial acute treatment or has stabilized enough that the focus shifts from crisis management to sustaining gains and improving long-term functioning. The FOA highlights post-acute strategies such as consolidating and maintaining improvements achieved during initial treatment, addressing residual symptoms and ongoing impairment, preventing relapse or recurrence, supporting adherence to ongoing care plans, and promoting appropriate service use over time. NIMH is looking for interventions and service models that are not only clinically sensible for this stage, but also appropriately calibrated in intensity and burden, meaning they should be strong enough to help, while also being feasible and acceptable for patients, families, and service systems to sustain.

A major feature of the announcement is its encouragement to go beyond simple "does it work" questions by testing scientifically grounded hypotheses about why and for whom an intervention works. Applicants are encouraged to examine moderators, mediators, and mechanisms of action. In practical terms, this means a trial might be designed to identify which subgroups benefit most (moderators, such as baseline severity, comorbidities, social determinants, or treatment history), what intermediate changes explain downstream outcomes (mediators, such as improved coping skills, increased engagement, reduced stress exposure, better medication adherence), and what processes drive the effects (mechanisms of action, such as changes in reward processing, threat reactivity, sleep regulation, family communication patterns, or care coordination pathways). The expectation is that effectiveness testing is paired with a thoughtful plan to interpret outcomes in a way that can guide future implementation and optimization.

This FOA is for an R01 and is labeled "Clinical Trial Required," meaning applications are expected to include a clinical trial that evaluates an intervention or service approach in a rigorous way. NIMH is signaling that these should not be small exploratory studies; rather, they should be powered to provide a definitive answer about the intervention's effectiveness in the target population and setting. If a project is still at the stage where feasibility, tolerability, acceptability, safety, or only preliminary signals of effectiveness need to be established, NIMH points applicants to a companion R34 mechanism (noted in the text as currently TEMP-11235) that is intended for pilot effectiveness trials. In other words, the R01 is meant for the more mature, ready-to-test stage where the field needs clear evidence that can inform clinical practice and service delivery.

Eligibility is broad and includes many types of domestic applicants such as state, county, city, township, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities. The announcement also explicitly welcomes applications from a wide range of mission-driven and community-embedded organizations and institutions, including faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American, Native American, and Pacific Islander serving institutions. Importantly, foreign organizations and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, reflecting NIMH's openness to international collaboration or non-U.S. research settings when scientifically justified.

From an administrative standpoint, the opportunity is categorized as discretionary grant funding under the health activity category, with CFDA (now commonly referenced via Assistance Listing) number 93.242, and it is administered by the National Institutes of Health. The source listing indicates an original closing date of 2025-01-25. While the excerpt does not provide an award ceiling or expected number of awards, the central message is clear: NIMH wants robust, real-world effectiveness trials that test post-acute interventions and service strategies designed to protect gains from initial care, reduce relapse and ongoing impairment, and improve long-term clinical and functional outcomes, while also generating evidence about how, why, and for whom these approaches are most beneficial.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
• This funding opportunity was created on 2021-04-01.
• Applicants must submit their applications by 2025-01-25. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 210

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: